Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Although the immune system plays a vital role in attacking tumor cells, the immune mechanisms vary from tumor to tumor, and factors in the tumor microenvironment can reduce the effectiveness of the body’s immune response.
Navigating Systemic Therapy for RCC: Balancing Risk Status and ResponseMarch 13th 2023
Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
Precision medicine has arrived in all stages of prostate cancer care and recommendations for optimal testing and how best to leverage the results to inform clinical decisions continue to rapidly evolve.
Radiotherapy Treatments Are Getting Shorter and Faster in Prostate Cancer
The history of radiation therapy for men with prostate cancer extends back more than a century. From those early crude methods, the field has advanced to delivery potentially curative therapies that can be administered in as little as 2 weeks.
Investigators Look Beyond Immune Checkpoint Inhibitors to Chase Moving Targets in Prostate CancerMarch 16th 2022
Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.
ADT-Based Combinations Have Become Standard Therapy for Metastatic Castration-Sensitive Prostate Cancer
Overwhelming evidence has pointed to the use of androgen deprivation therapy in combination with 1 or 2 other agents as the standard of care for patients with metastatic castration-sensitive prostate cancer.
Neoadjuvant Chemotherapy Benefit Retains Stronghold for Patients With MIBC, UTUCMarch 15th 2022
Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.
Immunotherapy and Targeted Treatment Approaches Improve Outcomes in Metastatic Urothelial Cancer
Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.
Frontline mRCC Paradigm Crowds Among Immune-Based Treatment OptionsMarch 13th 2021
The emergence of multiple combination regimens with immunotherapy and TKIs has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma; however, without head-to-head comparative data, treatment selection has become individualized based on available patient characteristics.
Novel Targeted and Immunotherapeutic Agents Reshape Metastatic Urothelial Cancer LandscapeMarch 12th 2021
Treatment options for patients with metastatic urothelial cancer have rapidly expanded as FDA approvals of immunotherapeutics push the boundaries of a once stagnant treatment landscape. Combination regimens and the addition of targeted approaches, further demonstrate progress in areas that have been tough to crack.
Immunotherapy Combinations Are King in Frontline RCC Treatment
In metastatic renal cell carcinoma, the use of frontline combination immunotherapy regimens has led to significant survival benefits for patients, and efforts are now being focused on exploring novel options for those who become refractory to this approach.
Dr. Gomella on the State of Genetic Testing and Screening in Prostate CancerMarch 14th 2020
Leonard G. Gomella, MD, professor, chair, Department of Urology, and director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the state of genetic testing in prostate cancer.
Dr. Pal on Biomarker Development in Renal Cell CarcinomaJuly 15th 2016
Sumanta Kumar Pal, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses biomarker development in the field of renal cell carcinoma (RCC).
Dr. Crawford on Ongoing Research With Radium-223 in mCRPCJuly 15th 2016
E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses ongoing research with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Dr. Stock on the Optimal Use of Radium-223 in mCRPCApril 25th 2016
Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer.
Dr. Choueiri on Using Immunotherapy to Treat RCCApril 11th 2016
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.
Dr. Gomella on Current Perspectives on Prostate Cancer ScreeningApril 1st 2016
Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and director of the Kimmel Cancer Center Network, discusses the current perspectives on screening for prostate cancer.
Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF PathwaysMarch 29th 2016
Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.
Dr. Petrylak on Immunotherapy in Bladder CancerMarch 28th 2016
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.